Participant flow

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma · Source last updated 2026-08-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   subjects with relapsed/refractory MCL

   id

   FG000

   title

   ACP-196 100 mg BID

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         59

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         10

      type

      Withdrawal by Subject

   3. reasons

      1. group Id

         FG000

         num Subjects

         51

      type

      study terminated by sponsor

   4. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Lost to Follow-up

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      SITE CLOSURE - PI RETIREMENT

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         124

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         124

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

For the ACE-LY-004 program, Study Terminated by Sponsor refers to the following: Patients receiving treatment benefits will continue to be provided with study medication in the Post Final Analysis Management of the trial. No further data collection for analysis and reporting will be completed after the final Analysis.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice